Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio de fase 1b/2 de BGB-11417 en monoterapia y en varias combinaciones con dexametasona y carfilzomib en mieloma múltiple

23 de octubre de 2026 actualizado por: BeOne Medicines

Estudio de fase 1b/2 de aumento de dosis y expansión de cohortes para determinar la seguridad y eficacia de BGB-11417 como monoterapia, en combinación con dexametasona y carfilzomib/dexametasona en pacientes con mieloma múltiple recidivante/refractario y t(11;14)

The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal translocation t(11;14).

The study investigates sonrotoclax alone and in combination with dexamethasone and other agents, including carfilzomib, daratumumab, and pomalidomide.

Descripción general del estudio

Descripción detallada

Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

246

Fase

  • Fase 2
  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • Aachen, Alemania, 52074
        • Reclutamiento
        • Universitaetsklinikum Aachen
      • Dresden, Alemania, 01307
        • Reclutamiento
        • Universitatsklinikum Carl Gustav Carus An Der Technischen Universitat Dresden
      • Hamburg, Alemania, 20251
        • Reclutamiento
        • Universitatsklinikum Hamburg Eppendorf
      • Würzburg, Alemania, 97080
        • Reclutamiento
        • Universitatsklinikum Wurzburg
    • Australian Capital Territory
      • Garran, Australian Capital Territory, Australia, ACT 2605
        • Reclutamiento
        • Canberra Hospital
    • New South Wales
      • Kingswood, New South Wales, Australia, NSW 2747
        • Reclutamiento
        • Nepean Hospital
    • Victoria
      • Clayton, Victoria, Australia, VIC 3168
        • Reclutamiento
        • Monash Health
      • Fitzroy, Victoria, Australia, VIC 3065
        • Reclutamiento
        • St Vincents Hospital Melbourne
      • Melbourne, Victoria, Australia, VIC 3004
        • Reclutamiento
        • The Alfred Hospital
    • Western Australia
      • Perth, Western Australia, Australia, WA 6000
        • Reclutamiento
        • Royal Perth Hospital
      • Brasília, Brasil, 70200-730
        • Reclutamiento
        • Hospital Sirio Libanes Brasilia
      • Brasília, Brasil, 70390140
        • Reclutamiento
        • Instituto Dor de Pesquisa E Ensino Distrito Federal
      • Porto Alegre, Brasil, 90110-270
        • Reclutamiento
        • Centro Gaucho Integrado de Oncologia Hospital Mae de Deus
      • Salvador, Brasil, 41253-190
        • Reclutamiento
        • Hospital Sao Rafael (Rede Dor)
      • São Paulo, Brasil, 05652-900
        • Reclutamiento
        • Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
      • São Paulo, Brasil, 01401-004
        • Reclutamiento
        • Instituto Dor de Pesquisa E Ensino Sao Paulo
      • São Paulo, Brasil, 01308-050
        • Reclutamiento
        • Hospital Sirio Libanes
    • Alberta
      • Edmonton, Alberta, Canadá, T6G 1Z2
        • Reclutamiento
        • Cross Cancer Institute
    • British Columbia
      • Vancouver, British Columbia, Canadá, V5Z 4E6
        • Reclutamiento
        • British Columbia Cancer Agency the Vancouver Centre
    • Ontario
      • Toronto, Ontario, Canadá, M5G 2M9
        • Reclutamiento
        • Princess Margaret Cancer Centre
    • Seoul Teugbyeolsi
      • GangnamGu, Seoul Teugbyeolsi, Corea del Sur, 06351
        • Reclutamiento
        • Samsung Medical Center
      • SeochoGu, Seoul Teugbyeolsi, Corea del Sur, 06591
        • Reclutamiento
        • The Catholic University of Korea, Seoul St Marys Hospital
      • SeodaemunGu, Seoul Teugbyeolsi, Corea del Sur, 03722
        • Reclutamiento
        • Severance Hospital Yonsei University Health System
      • Seoul, Seoul Teugbyeolsi, Corea del Sur, 03080
        • Reclutamiento
        • Seoul National University Hospital
      • SongpaGu, Seoul Teugbyeolsi, Corea del Sur, 05505
        • Reclutamiento
        • Asan Medical Center
      • Barcelona, España, 08036
        • Activo, no reclutando
        • Hospital Clinic de Barcelona
    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35294-0004
        • Reclutamiento
        • University of Alabama At Birmingham Hospital
    • California
      • Duarte, California, Estados Unidos, 91010-3012
        • Reclutamiento
        • City of Hope National Medical Center
      • Irvine, California, Estados Unidos, 92618-2377
        • Reclutamiento
        • City of Hope Irvine Lennar
    • Florida
      • Miami, Florida, Estados Unidos, 33136-2107
        • Reclutamiento
        • University of Miami
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322-1013
        • Reclutamiento
        • Emory University Winship Cancer Center
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60637-1443
        • Reclutamiento
        • University of Chicago Medical Center
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02114
        • Terminado
        • Massachusetts General Hospital
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63110-1010
        • Reclutamiento
        • Washington University School of Medicine
    • New Jersey
      • Hackensack, New Jersey, Estados Unidos, 07601-1915
        • Reclutamiento
        • Hackensack University Medical Center
    • New York
      • New York, New York, Estados Unidos, 10065-6800
        • Reclutamiento
        • Memorial Sloan Kettering Cancer Center Mskcc
    • Ohio
      • Columbus, Ohio, Estados Unidos, 43210-1240
        • Reclutamiento
        • The James Cancer Hospital and Solove Research Institute At Ohio State University
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84112-5550
        • Reclutamiento
        • Huntsman Cancer Institute
    • Washington
      • Seattle, Washington, Estados Unidos, 98195
        • Reclutamiento
        • University of Washington
    • Wisconsin
      • Madison, Wisconsin, Estados Unidos, 53792-0001
        • Reclutamiento
        • University of Wisconsin Carbone Cancer Center
      • Milwaukee, Wisconsin, Estados Unidos, 53226-3522
        • Reclutamiento
        • Medical College of Wisconsin
      • Poitiers, Francia, 86000
        • Terminado
        • Chu de Poitiers Site de La Mileterie
      • Alexandroupoli, Grecia, 68100
        • Reclutamiento
        • University Hospital of Alexandroupolis
      • Athens, Grecia, 115 28
        • Reclutamiento
        • General Hospital of Athens Alexandra
      • Ancona, Italia, 60020
        • Reclutamiento
        • Azienda Ospedaliera Universitaria Delle Marche
      • Bari, Italia, 70124
        • Reclutamiento
        • Azienda Ospedaliera Policlinico Di Bari
      • Bologna, Italia, 40138
        • Reclutamiento
        • Policlinico Sorsola Malpighi, Aou Di Bologna
      • Meldola, Italia, 47014
        • Reclutamiento
        • Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst
      • Milan, Italia, 20141
        • Reclutamiento
        • Istituto Europeo Di Oncologia
    • Beijing Municipality
      • Beijing, Beijing Municipality, Porcelana, 100044
        • Reclutamiento
        • Peking University Peoples Hospital
      • Beijing, Beijing Municipality, Porcelana, 100000
        • Reclutamiento
        • Peking University Third Hospital
      • Beijing, Beijing Municipality, Porcelana, 100020
        • Reclutamiento
        • Beijing Chao Yang Hospital
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, Porcelana, 400030
        • Reclutamiento
        • Chongqing Cancer Hospital
    • Fujian
      • Fuzhou, Fujian, Porcelana, 350001
        • Terminado
        • Fujian Medical University Union Hospital
      • Xiamen, Fujian, Porcelana, 361003
        • Terminado
        • The First Affiliated Hospital of Xiamen University
    • Guangdong
      • Guangzhou, Guangdong, Porcelana, 510060
        • Reclutamiento
        • Sun Yat Sen University Cancer Center
    • Hebei
      • Shijiazhuang, Hebei, Porcelana, 050000
        • Terminado
        • The Second Hospital of Hebei Medical University
    • Henan
      • Zhengzhou, Henan, Porcelana, 450000
        • Reclutamiento
        • Henan Cancer Hospital
      • Zhengzhou, Henan, Porcelana, 450052
        • Activo, no reclutando
        • The First Affiliated Hospital of Zhengzhou University
    • Hubei
      • Wuhan, Hubei, Porcelana, 430022
        • Reclutamiento
        • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
    • Hunan
      • Changsha, Hunan, Porcelana, 410013
        • Terminado
        • Hunan Cancer Hospital
    • Jiangsu
      • Nanjing, Jiangsu, Porcelana, 210029
        • Reclutamiento
        • Jiangsu Province Hospital
    • Jiangxi
      • Nanchang, Jiangxi, Porcelana, 332000
        • Reclutamiento
        • The First Affiliated Hospital of Nanchang University Branch Xianghu
    • Liaoning
      • Shenyang, Liaoning, Porcelana, 110001
        • Reclutamiento
        • The First Hospital of China Medical University
    • Shandong
      • Qingdao, Shandong, Porcelana, 266000
        • Reclutamiento
        • Qingdao Municipal Hospital
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Porcelana, 200032
        • Reclutamiento
        • Affiliated Zhongshan Hospital of Fudan University
      • Shanghai, Shanghai Municipality, Porcelana, 200434
        • Terminado
        • Shanghai Fourth Peoples Hospital Affiliated to Tongji University
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Porcelana, 301617
        • Reclutamiento
        • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciencestuanbo Branch
      • Tianjin, Tianjin Municipality, Porcelana, 300052
        • Terminado
        • Tianjin Medical University General Hospital
    • Zhejiang
      • Hangzhou, Zhejiang, Porcelana, 310003
        • Reclutamiento
        • The First Affiliated Hospital, Zhejiang University School of Medicine
      • Headington, Reino Unido, OX3 7LE
        • Reclutamiento
        • Oxford University Hospitals Nhs Trust Churchill Hospital
      • London, Reino Unido, NW1 2PG
        • Reclutamiento
        • University College Hospital
      • Sutton, Reino Unido, SM2 5PT
        • Reclutamiento
        • Royal Marsden Nhs Foundation Royal Marsden Hospital
      • Singapore, Singapur, 119074
        • Reclutamiento
        • National University Hospital Singapore

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

  2. A confirmed diagnosis of multiple myeloma (must have an M-component in serum and/or urine)

  3. Measurable disease defined as:

    i. M-spike ≥ 500mg/dL, or ii. Urine protein M-spike of ≥ 200 mg/day, or iii. Serum free light chains ≥ 10 mg/dL, and an abnormal κ:λ ratio

  4. Participant has documented relapsed or progressive MM on or after any regimen or who are refractory to the most recent line of therapy.

    i. Relapsed MM is defined as previously treated MM that progresses and requires initiation of salvage therapy but does not meet the criteria for refractory MM.

    ii. Refractory MM is defined as disease that is nonresponsive (failure to achieve minimal response or development of progressive disease) while on primary or salvage therapy or progresses within 60 days of last therapy.

    1. In Part 1 and Part 2 Cohorts 1 and 2 participants should have relapsed or progressive disease and have had ≥ 3 prior lines of therapy including a proteasome inhibitor, an IMiD, and an anti-CD38 monoclonal antibody, and no more available approved therapies.
    2. Participants in Part 2 Cohorts 3, 4, and 5 should have relapsed or progressive disease and have had ≥ 1 prior line of therapy. Prior treatment with carfilzomib is allowed but the patient must not be considered carfilzomib refractory by the investigator.
    3. Participants in Part 2 Cohorts 6 and 7 should have relapsed or progressive disease and have had 1 to 3 prior lines of therapy and previously treated with a proteasome inhibitor and an IMiD
  5. Positivity for t(11;14) translocation must be confirmed by validated fluorescence in situ hybridization (FISH) testing assay in a pre-defined laboratory

    a. fresh bone marrow aspirate sample must be collected at screening and sent to central laboratory for t(11;14) FISH testing.

  6. Adequate organ function defined as:

    1. Hemoglobin ≥ 8.0 g/dL within 7 days before first dose of study treatment, (transfusions, in accordance with institutional guidelines, are permitted)
    2. Platelet count ≥ 75,000/μL, within 7 days before first dose of study treatment, independent of growth factor support and transfusions
    3. Absolute neutrophil count (ANC) ≥ 1000/mm^3 within 7 days before first dose of study treatment
    4. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x upper limit of normal (ULN) and total bilirubin ≤ 2.0 x ULN N (total bilirubin must be < 3 x ULN for patients with Gilbert's syndrome)

Exclusion Criteria:

  1. Participant has any of the following conditions:

    1. Non secretory MM (Serum free light chains < 10 mg/dL)
    2. Solitary plasmacytoma
    3. Active plasma cell leukemia (ie, either 20% of peripheral white blood cells or > 2.0 x 109/L circulating plasma cells by standard differential)
    4. Waldenström macroglobulinemia (WM)
    5. Amyloidosis.
    6. Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes (POEMS) syndrome
    7. Chronic respiratory disease that requires continuous oxygen
  2. Significant cardiovascular disease, including but not limited to:

    1. Myocardial infarction ≤ 6 months before screening
    2. Ejection fraction ≤ 50%
    3. Unstable angina≤ 3 months before screening
    4. New York Heart Association Class III or IV congestive heart failure
    5. History of clinically significant arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, or torsades de pointes)
    6. Heart rate-corrected QT interval > 480 milliseconds based on Fridericia's formula
    7. History of Mobitz II second-degree or third-degree heart block without a permanent pacemaker in place
    8. Uncontrolled hypertension at screening, defined as systolic blood pressure > 170 mmHg and diastolic blood pressure > 105 mmHg by ≥ 2 consecutive measurements. Prior therapy with sonrotoclax or other agents inhibiting BCL2 activity (eg, venetoclax)
  3. Known infection with human immunodeficiency virus (HIV)

  4. Serologic status reflecting active viral hepatitis B (HBV) or viral hepatitis C (HCV) infection as follows:

    1. Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). Participants with presence of HBcAb, but absence of HBsAg, are eligible if HBV DNA is undetectable (limitation of sensitivity < 20 IU/mL) ,), and if they are willing to undergo monthly monitoring for HBV reactivation.
    2. Presence of HCV antibody. Participants with presence of HCV antibody are eligible if HCV RNA is undetectable (limitation of sensitivity < 15 IU/mL).

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Part 1 Dose Escalation

Dose-escalation and de-escalation to determine maximum tolerated dose (MTD) of sonrotoclax plus dexamethasone, sonrotoclax plus dexamethasone plus carfilzomib, sonrotoclax plus dexamethasone plus daratumumab, and sonrotoclax plus dexamethasone plus pomalidomide.

Administered orally daily

Otros nombres:
  • BGB-11417

Once weekly either orally or intravenously

Administered intravenously weekly

Administered subcutaneously weekly

Administered orally daily

Experimental: Part 2 Cohort Expansion

There will be up to 7 expansion cohorts to further evaluate the safety and efficacy of sonrotoclax monotherapy, sonrotoclax plus dexamethasone in combination with dexamethasone plus carfilzomib, and in combination with dexamethasone plus daratumumab

Administered orally daily

Otros nombres:
  • BGB-11417

Once weekly either orally or intravenously

Administered intravenously weekly

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Parte 1 y 2: Número de participantes que informan uno o más eventos adversos emergentes de tratamiento (TEAE), eventos adversos graves (SAE), eventos adversos que conducen a la interrupción y eventos adversos de especial interés (AESI).
Periodo de tiempo: Hasta 30 días después de la última dosis de droga de estudio
Hasta 30 días después de la última dosis de droga de estudio
Part 1: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs)
Periodo de tiempo: Up to 28 days

DLTs will be based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 and will include most grade 3 or higher events, as defined in the protocol.

Up to 28 days
Part 2: Overall response rate (ORR) as Assessed by Investigator
Periodo de tiempo: Approximately 4 years

Defined as the percentage of participants who achieved a stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) per International Myeloma Working Group (IMWG) criteria

Approximately 4 years
Part 2: Very Good Partial Response (VGPR) or Better Response Rate as Assessed by Investigator
Periodo de tiempo: Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years]

Defined as the percentage of participants with a documented VGPR or better (including sCR, CR, and VGPR)

Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years]
Part 2: Complete Response (CR) or Stringent Complete Response (sCR) as Assessed by Investigator
Periodo de tiempo: Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years])

defined as the percentage of participants with a documented CR or sCR

Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years])

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Parte 1: Área bajo el tiempo de curva de tiempo de concentración plasmática 0 a la última concentración medible (auclast) después de una sola dosis de sonrotoclax
Periodo de tiempo: Ciclo 1 (cada ciclo es de hasta 28 días)
Ciclo 1 (cada ciclo es de hasta 28 días)
Parte 1: Concentración plasmática máxima observada (CMAX) después de una dosis única de Sonrotoclax
Periodo de tiempo: Ciclo 1 (cada ciclo es de hasta 28 días)
Ciclo 1 (cada ciclo es de hasta 28 días)
Parte 1: Tiempo para llegar a CMAX (TMAX) después de una dosis única de Sonrotoclax
Periodo de tiempo: Ciclo 1 (cada ciclo es de hasta 28 días)
Ciclo 1 (cada ciclo es de hasta 28 días)
Parte 1: En Estado Estable: AUC Last, SS
Periodo de tiempo: Ciclo 2 (cada ciclo es de hasta 28 días)
Ciclo 2 (cada ciclo es de hasta 28 días)
Parte 1: En Estado Estable: CMAX, SS
Periodo de tiempo: Ciclo 2 (cada ciclo es de hasta 28 días)
Ciclo 2 (cada ciclo es de hasta 28 días)
Parte 1: En estado estacionario: concentración de plasma mínimo (CTROUGH) SS
Periodo de tiempo: Ciclo 2 (cada ciclo es de hasta 28 días)
Ciclo 2 (cada ciclo es de hasta 28 días)
Parte 1: En estado estacionario: tiempo para llegar a CMAX (TMAX, SS)
Periodo de tiempo: Ciclo 2 (cada ciclo es de hasta 28 días)
Ciclo 2 (cada ciclo es de hasta 28 días)
Part 2: Time to response (TTR) as Assessed by Investigator
Periodo de tiempo: Approximately 4 years

TTR is defined as the time from start of treatment (for nonrandomized cohorts) or date of randomization (for randomized cohorts to first documentation of response of Partial Response (PR) or better

Approximately 4 years
Part 2: Duration of response (DOR) as Assessed by Investigator
Periodo de tiempo: Approximately 4 years

DOR is defined as the time from the date of the first documented response (PR or better) after treatment initiation until the date of first documented disease progression or death due to any cause, whichever occurs first. DOR will be analyzed only for patients who have achieved an overall response of at least PR. The distribution of DOR will be summarized by the Kaplan-Meier method.

Approximately 4 years
Part 2: Progression-free survival (PFS) as Assessed by Investigator
Periodo de tiempo: Approximately 4 years

PFS is defined as time from start of treatment (for nonrandomized cohorts) or date of randomization (for randomized cohorts) to the first documentation of disease progression or death, whichever occurs first

Approximately 4 years
Part 2: Overall survival (OS) as Assessed by Investigator
Periodo de tiempo: Approximately 4 years

OS defined as the time from start of treatment (for nonrandomized cohorts) or date of randomization (for randomized cohorts to the date of death due to any cause

Approximately 4 years

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

16 de septiembre de 2021

Finalización primaria (Estimado)

1 de noviembre de 2026

Finalización del estudio (Estimado)

1 de noviembre de 2026

Fechas de registro del estudio

Enviado por primera vez

7 de julio de 2021

Primero enviado que cumplió con los criterios de control de calidad

20 de julio de 2021

Publicado por primera vez (Actual)

22 de julio de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

26 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

23 de octubre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.

BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.

Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Marco de tiempo para compartir IPD

See plan description

Criterios de acceso compartido de IPD

See plan description

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • RSC

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir